n (%) | |
---|---|
Patients enrolled and CM administered:1 | 515 |
Male sex | 377 (73.2) |
Age (mean±SD) | 60±10.3 years |
Body mass index (mean±SD) | 28.2±4.3 kg/m2 |
Risk factors: | |
Hypertension | 358 (69.5) |
Hypercholesterolemia | 354 (68.8) |
Diabetes | 92 (17.8) |
History of heart failure | 106 (20.6) |
Myocardial infarction | 139 (27.0) |
Percutaneous coronary intervention (PCI) | 170 (33.0) |
Angina pectoris | 414 (80.4) |
CCS I | 87 (16.9) |
CCS II | 227 (44.1) |
CCS III | 46 (8.9) |
CCS IV | 21 (4.1) |
Patients with all 3 test data sets complete (efficacy population): | n 465 |
Coronary artery disease | 227 (48.8) |
Left main | 14 (3.0) |
LAD | 134 (28.8) |
LCX | 104 (22.4) |
RCA | 112 (24.1) |
Multivessel disease | 113 (24.3) |
Myocardial infarction | 129 (27.7) |
Medication: | |
Any drugs | 496 (96.4) |
Beta-blockers | 367 (71.3) |
Lipid lowering | 354 (68.8) |
Angiotensin-converting enzyme inhibitors | 306 (59.4) |
Diuretics | 131 (25.5) |
Calcium channel blockers | 99 (19.2) |
Antithrombotic | 425 (82.6) |
MR – not evaluable | 26 (5.6) |
SPECT – not evaluable | 17 (3.7) |